Skip to main content

Epanova FDA Approval History

FDA Approved: Yes (Discontinued) (First approved May 5, 2014)
Brand name: Epanova
Generic name: omega-3-carboxylic acids
Dosage form: Capsules
Company: AstraZeneca
Treatment for: Hypertriglyceridemia

Marketing Status: Discontinued

Epanova (omega-3-carboxylic acids) is a fish oil-derived mixture of free fatty acids for the treatment of patients with severe hypertriglyceridemia.

Development timeline for Epanova

DateArticle
May  6, 2014Approval FDA Approves Epanova for Severe Hypertriglyceridemia
Sep 18, 2013FDA Accepts New Drug Application for Investigational Compound Epanova for the Treatment of Severe Hypertriglyceridemia
Jul  9, 2013Omthera Pharmaceuticals Announces NDA Submission for Epanova for the Treatment of Patients with Very High Triglycerides

See also

Epanova (omega-3-carboxylic acids) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer